SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (271)10/10/2005 4:31:38 PM
From: tuck  Read Replies (1) | Respond to of 447
 
From Genentech's quarterly PR just out:

>>U.S. sales of Tarceva® (erlotinib) were $73.2 million. Sequential
quarter-over-quarter Tarceva sales increased 4 percent from second
quarter 2005 U.S. sales of $70.2 million. Tarceva was launched in the
United States in November 2004.<<

Weaker than expected, which probably explains the weakness in the stock of late.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News